Browse online courses created through SITC’s collaborative partnerships.

Collaborative Partnership Courses
Collapse Case Studies in Lung Cancer: Test Your Skills

Access Course

 

Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices—order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface. Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

 

This activity is intended for hematologist/oncologist specialists.

 

The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the diagnosis, biomarker testing, evidence-based frontline treatment, and potential treatment-related adverse events of patients with advanced lung cancer.

 

Learning Objectives:

  • Select appropriate diagnostic and biomarker tests to guide treatment selection for a patient with advanced lung cancer.
  • Order an appropriate, evidence-based frontline treatment regimen for a patient with advanced lung cancer.
  • Provide patient education for potential treatment-related adverse events.

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Mar. 18, 2020 - Mar. 18, 2021

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

Additional Lung Cancer Resources for Clinicans from SITC:

 

sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

 

 

 

View Guidelines Here.

View On-demand Webinar Here.

Original Course Date: March 19, 2020

Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Case Studies in Lung Cancer: Test Your Skills
    Collapse Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?

    Access Course

     

    Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?Experts discuss the use of checkpoint inhibition in metastatic melanoma as well as its expansion into the adjuvant setting and beyond.

     

    This activity is intended for oncologists, dermatologists, and other healthcare professionals who treat patients with melanoma.

     

    The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of melanoma.

     

    Learning Objectives:

    • Have increased knowledge regarding the emerging clinical trials data on the use of immune-modulating agents in the management of melanoma
    • Have increased knowledge regarding the place in therapy for immune checkpoint inhibitors in patients with melanoma

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 4, 2020 - Mar. 4, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Melanoma Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma" (Published May 30, 2018)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: March 04, 2020

    Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Spotlight on the Future of Treatment Algorithms in Melanoma: Where Are We Headed?
    Collapse Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCC

    Access Course

     

    Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCCWatch experts discuss the latest data in immunotherapy as well as strategies for managing patients with advanced RCC.

     

    This activity is intended for oncologists, urologists, nephrologists, nurses and nurse practitioners, pharmacists, and other healthcare providers who manage patients with renal cell carcinoma (RCC).

     

    The goal of this activity is to increase understanding of the latest advances in the use of checkpoint inhibition in patients with advanced RCC.

     

    Learning Objectives:

    • Have increased knowledge regarding the emerging clinical trial data on the use of immune checkpoint inhibitors (ICIs) and other immunotherapies alone or in combination in the treatment of advanced RCC
    • Have increased knowledge regarding the impact of recent clinical data on the treatment paradigm for patients with advanced RCC
    • Demonstrate greater confidence in their ability to work with the interprofessional team to recognize and mitigate adverse events (AEs) in patients with advanced RCC

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 30, 2020 - Jan. 30, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    Additional Lung Cancer Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" (Published December 20, 2019)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: January 30, 2020

    Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.05 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Expert Insights on Emerging Data for the Use of Immunotherapy in Advanced RCC
    Collapse Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCC

    Access Course

     

    Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCCDrs Pal and Hammers discuss data and clinical pearls for the use of checkpoint inhibitors in RCC.

     

    This activity is intended for hematologists/oncologists and urologists.

     

    The goal of this activity is to improve knowledge and competence related to the role of immune checkpoint inhibitors (ICIs) as monotherapy and combination therapy for patients with renal cell carcinoma (RCC).

     

    Learning Objectives:

    • Have increased knowledge regarding the clinical trial data related to ICIs for the treatment of RCC
    • Have greater competence related to selecting patients with RCC who are appropriate candidates to receive ICI therapy

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 21, 2020 - Jan. 21, 2021

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)" (Published December 20, 2019)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: January 21, 2020

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Updates in the Role of Immune Checkpoint Inhibitors for the Management of RCC
    Collapse Novel Insights Into the Use of Immune Checkpoint Inhibitors in Lung Cancer

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

     

    This activity is intended for hematologists/oncologists, pulmonologists, pathologists, nurses, and pharmacists.

     

    The goal of this activity is to improve knowledge regarding recent clinical trial data on the use of immune checkpoint inhibitors (ICIs) alone or in combination in advanced lung cancers.

     

    Learning Objectives:

    • Have increased knowledge regarding the emerging clinical trial data on the use of ICIs alone or in combination with other cancer immunotherapies in the management of advanced lung cancers
    • Have increased knowlege regarding the impact of recent clinical data on treatment strategies for patients with advanced lung cancers in the community oncology setting

     

    Approximate Time to Complete: 45 minutes

     

    Credit Available: Dec. 26, 2019 - Dec. 26, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: December 26, 2019

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.08 hours CEU
  • ANCC: 0.75 hours Contact Hour

  • MORE INFOMORE INFO Novel Insights Into the Use of Immune Checkpoint Inhibitors in Lung Cancer
    Collapse Going Beyond PD-(L)1 Inhibition: Where Can Manipulating the Immune System take Cancer Care?

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Learn about agents that target pathways in solid tumors other than PD-1/PD-L1

     

    This activity is intended for hematologists/oncologists, nurses, and pharmacists.

     

    The goal of this activity is to improve knowledge regarding immunotherapy pathways beyond programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1), and data for agents that target these pathways.

     

    Learning Objectives:

    • Have increased knowledge regarding the common strategies and pathways beyond PD-(L)1 that cancer cells harness to avoid detection by the immune system
    • Have increased knowledge regarding the mechanisms of action (MOAs) of emerging cancer immunotherapies
    • Have increased knowledge regarding the scientific rationale for evaluating and integrating cancer immunotherapy throughout the continuum of care for patients with cancer

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 26, 2019 - Dec. 26, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: December 26, 2019

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.05 hours CEU
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Going Beyond PD-(L)1 Inhibition: Where Can Manipulating the Immune System take Cancer Care?
    Collapse Optimizing Outcomes in Melanoma: A Case Challenge

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Apply best practices to the diagnosis and management of patients with melanoma.

     

    This activity is intended for hem/onc specialists, dermatologists, emergency medicine physicians, and nurse practitioners.

     

    The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the work-up, treatment, and follow-up of patients with melanoma.

     

    Learning Objectives:

    • Demonstrate improved performance associated with assessing patients to determine appropriate treatment strategies for melanoma
    • Demonstrate improved performance associated with identifying an appropriate, evidence-based treatment regimen for a patient with melanoma
    • Demonstrate improved performance associated with utilizing an interprofessional team approach to identify and provide patient education around adverse event management in the treatment of melanoma

     

    Approximate Time to Complete: 60 minutes

     

    Credit Available: Dec. 13, 2019 - Dec. 13, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png     

    Medscape_EDU-RGB-2x-300.png

     

    sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma" (Published May 30, 2018)

     

     

     

    View Guidelines Here.

    View On-demand Webinar Here.

    Original Course Date: December 13, 2019

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Optimizing Outcomes in Melanoma: A Case Challenge
    Collapse The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors

    Access Course

     

    The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?Experts discuss pressing issues related to checkpoint inhibitor use, including irAEs and use in autoimmune disease and organ transplant.

     

    This activity is intended for nurses, nurse practitioners, and other healthcare professionals who treat cancer patients with immune checkpoint inhibitors.

     

    The goal of this activity is to increase understanding of the issues surrounding immune checkpoint inhibitors (ICIs), including the risk for immune-related adverse events (irAEs) and optimal patient/caregiver communication.

     

    Learning Objectives:

    • Have increased knowledge regarding the factors, such as medications and a patient's medical history, that may influence the efficacy of ICIs in patients with cancer
    • Have greater competence related to optimizing communication between the cancer care team and the patient/caregiver related to irAEs, including reporting and identifying toxicities
    • Have greater competence related to applying best nursing practices in the management of irAEs

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 25, 2019 - Nov. 25, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png

     

    Additional Resources from SITC:

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: November 27, 2019

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors
    Collapse Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers

    Access Course

     

    Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers

    The latest advances in immunotherapy for CRC, HCC, and gastroesophageal cancers are explored in these 3 columns.

     

    This activity is intended for oncologists, gastroenterologists, and other healthcare professionals who treat patients with gastrointestinal (GI) cancers.

     

    The goal of this activity is to increase understanding of the advances and challenges of using checkpoint inhibitors in the treatment of patients with GI cancers.

     

    Learning Objectives:

    • Have increased knowledge regarding the clinical trial data on the use of immune checkpoint inhibitors (ICIs) alone or in combination in patients with advanced or metastatic GI cancers
    • ICI treatment strategies for patients with GI cancers in the community oncology setting

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: November 27, 2019 - November 27, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

     

     

     

    View Available Guidelines Here.

    Original Course Date: November 27, 2019

    Approved Credit:
  • ACCME: 1 hour AMA PRA Category 1 Credit(s)
  • ABIM: 1 hour ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Opportunities and Possibilities: Cancer Immunotherapy in the Management of GI Cancers
    Collapse Best Practices in the Management of SCCHN With Checkpoint Inhibition

    Access Course

     

    Best Practices in the Management of SCCHN With Checkpoint InhibitionDr Dan Zandberg reviews the latest understanding in the use of checkpoint inhibition in SCCHN through an examination of 3 cases.

     

    This activity is intended for oncologists, surgeons, and pathologists.

     

    The goal of this activity is to increase understanding of the use of checkpoint inhibition in advanced squamous cell carcinoma of the head and neck (SCCHN) as well as ongoing research into its use earlier in the disease setting.

     

    Learning Objectives:

    • Have increased knowledge regarding the evidence-based management of patients with SCCHN
    • Have increased knowledge regarding the role of cancer immunotherapy clinical trials
    • Have greater competence related to selecting the most appropriate cancer immunotherapy regimen for patients with SCCHN
    • Have greater competence related to managing immune-related adverse effects

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: May 9, 2019 - May 9, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png

     

    Additional Resources for Clinicans from SITC:

     

    sitc-cig-rgb.png

    "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)" (Published July 15, 2019)

     

     

     

    View Guidelines Here.

    View On-Demand Webinar Here.

    Original Course Date: May 09, 2019

    Approved Credit:
  • ACCME: 1 hour AMA PRA Category 1 Credit(s)
  • ABIM: 1 hour ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Best Practices in the Management of SCCHN With Checkpoint Inhibition
    Collapse Patient-Centered Care in Advanced Bladder Cancer

    Access Course

     

    Patient-Centered Care in Advanced Bladder CancerExperts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.

    This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with bladder cancer.

    The goal of this activity is to discuss the role of immunotherapy, including how to determine eligibility and how to manage immune-related adverse events (irAEs), in the treatment of advanced bladder cancer.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Apr. 30, 2019- Apr. 30, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 30, 2019

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Patient-Centered Care in Advanced Bladder Cancer
    Collapse The Nurse View: Modulating the Immune System in GI Cancers

    Access Course

     

    The Nurse View: Modulating the Immune System in GI CancersNursing experts discuss the emergence of immunotherapy in GI cancers, focusing on the role of biomarkers and the management of irAEs.

     

    This activity is intended for nurses and other healthcare professionals who manage patients with gastrointestinal cancers.

     

    The goal of this activity is to discuss the emerging role of immunotherapy using immune checkpoint inhibitors in patients with gastrointestinal cancers.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Apr. 30, 2019 - Apr. 30, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 30, 2019

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO The Nurse View: Modulating the Immune System in GI Cancers
    Collapse Management of Advanced Bladder Cancer: What You Should Know

    Access Course

     

    This article is for people who have advanced bladder cancer or anyone who wants to learn more about advanced bladder cancer. The goal of this patient education activity is to make patients more aware of available treatment options for advanced bladder cancer.

     

     

     

     

     

    You will learn about:

     

    • What chemotherapy is and how it is used to treat advanced bladder cancer
    • What checkpoint inhibitors are and how they are used to treat advanced bladder cancer
    • The potential side effects of chemotherapy and checkpoint inhibitors
    • Why the side effects from chemotherapy and checkpoint inhibitors are different
    • Questions to ask your doctor

     

    Available beginning: April 26, 2019

     

    Approximate Time to Complete: 30 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 26, 2019
    MORE INFOMORE INFO Management of Advanced Bladder Cancer: What You Should Know
    Collapse Melanoma: Steps to Optimizing Clinical Outcomes

    Access Course

    Explore the latest in melanoma care through 2 cases, one in the adjuvant setting and one in the metastatic setting.

     

    This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with melanoma.

     

     

     

     

    Credit Available: Feb. 25, 2019 - Feb. 25, 2020

     

    Approximate Time to Complete: 75 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 25, 2019
    MORE INFOMORE INFO Melanoma: Steps to Optimizing Clinical Outcomes